NeuCyte is a biotech company focused on generating quality iPSC-derived neural cells to develop treatments for neurological disorders. Our vision and approach span many biopharmaceutical sectors as our technology is utilized to find treatments and solutions for AD, ALS/FTD, rare diseases and disorders, epilepsy, autism and other neurodegenerative diseases.
What started with an idea has now advanced to an advantageous, proprietary human iPSC-based technology platform for CNS disease modeling, target validation, custom cell production, and compound screening. With both human biology and high throughput screening our system can be used to develop therapeutic agents of a wide variety for many disease areas.
Our robust platform allows us to differentiate iPS cells from any background into a range of neural cell types, including neurons, astrocytes, and microglia with a 100% success rate. Our assay capabilities include a wide range of electrophysiology and high content imaging systems, as well as genomic and biochemical analysis, the combination of which provide neural functional assessment for our clients. This powerful and comprehensive foundation makes the NeuCyte platform a rigorous and reproducible system that can be used to screen therapeutic agents of a wide variety for many disease areas, with significant interest and effort to help serve rare disease communities.
